Clariane Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Clariane is gedaald met een gemiddeld jaarlijks percentage van -50.9%, terwijl de winst van de Healthcare -industrie jaarlijks groeide met 11.5%. De inkomsten zijn groeide met een gemiddeld percentage van 8.2% per jaar.

Belangrijke informatie

-50.9%

Groei van de winst

-98.3%

Groei van de winst per aandeel

Healthcare Groei van de industrie	13.4%
Inkomstengroei	8.2%
Rendement op eigen vermogen	-3.0%
Nettomarge	-2.5%
Volgende winstupdate	24 Feb 2025

Recente prestatie-updates uit het verleden

Recent updates

Here's Why Clariane (EPA:CLARI) Has A Meaningful Debt Burden

Sep 13

Clariane SE's (EPA:CLARI) 26% Cheaper Price Remains In Tune With Revenues

Aug 06

Here's Why It's Unlikely That Clariane SE's (EPA:CLARI) CEO Will See A Pay Rise This Year

Jun 04

Clariane SE (EPA:CLARI) Shares Could Be 33% Below Their Intrinsic Value Estimate

May 22

Market Participants Recognise Clariane SE's (EPA:CLARI) Revenues Pushing Shares 187% Higher

May 22

Opbrengsten en kosten

Hoe Clariane geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

ENXTPA:CLARI Opbrengsten, kosten en inkomsten (EUR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 24	5,170	-129	565
31 Mar 24	5,083	-111	555
31 Dec 23	4,996	-92	545
30 Sep 23	4,865	-32	527
30 Jun 23	4,735	28	509
31 Mar 23	4,587	32	483
31 Dec 22	4,438	36	458
30 Jun 22	4,288	85	439
31 Mar 22	4,212	92	434
31 Dec 21	4,137	100	430
30 Sep 21	4,047	76	404
30 Jun 21	3,941	60	425
31 Mar 21	3,857	50	431
31 Dec 20	3,773	39	437
30 Sep 20	3,728	57	446
30 Jun 20	3,683	74	456
31 Mar 20	3,648	94	452
31 Dec 19	3,613	115	449
30 Sep 19	3,542	117	528
30 Jun 19	3,471	119	607
31 Mar 19	3,404	121	686
31 Dec 18	3,336	123	765
30 Sep 18	3,280	152	755
30 Jun 18	3,224	180	744
31 Mar 18	3,177	172	739
31 Dec 17	3,131	163	735
30 Sep 17	3,091	150	736
30 Jun 17	3,052	137	738
31 Mar 17	3,017	134	733
31 Dec 16	2,981	131	728
30 Sep 16	2,880	87	706
30 Jun 16	2,779	42	684
31 Mar 16	2,676	50	674
31 Dec 15	2,573	59	664
30 Sep 15	2,553	77	664
30 Jun 15	2,533	95	664
31 Mar 15	2,378	78	631
31 Dec 14	2,222	61	597
30 Sep 14	1,938	44	526
30 Jun 14	1,654	27	455
31 Mar 14	1,505	28	423
31 Dec 13	1,356	29	391

Kwaliteitswinsten: CLARI is momenteel verliesgevend.

Groeiende winstmarge: CLARI is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: CLARI is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 50.9% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van CLARI over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: CLARI is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Healthcare industrie ( 12.1% ).

Rendement op eigen vermogen

Hoge ROE: CLARI heeft een negatief Return on Equity ( -2.99% ), omdat het momenteel verliesgevend is.

Clariane Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Clariane SE to Report Fiscal Year 2024 Results on Feb 24, 2025

Full year 2023 earnings released

Clariane SE to Report First Half, 2024 Results on Jul 30, 2024

Clariane SE to Report Fiscal Year 2023 Results on Feb 28, 2024

First half 2023 earnings released

Full year 2022 earnings released

Recent updates

Clariane SE, Annual General Meeting, May 14, 2025

Clariane SE to Report Fiscal Year 2024 Results on Feb 24, 2025

Clariane Group Announces Management Changes

Here's Why Clariane (EPA:CLARI) Has A Meaningful Debt Burden

Clariane Se Provides Earnings Guidance for the Full Year 2024; Reiterates Earnings Guidance for the Full Year from 2023 to 2026

Clariane SE's (EPA:CLARI) 26% Cheaper Price Remains In Tune With Revenues

New major risk - Shareholder dilution

Now 20% undervalued

Odalys SA acquired Les Essentielles - SARL from Clariane SE (ENXTPA:CLARI).

Price target increased by 82% to €7.90

New minor risk - Shareholder dilution

Clariane SE has filed a Follow-on Equity Offering in the amount of €237.083186 million.

Clariane SE Appoints Sylvia Metayer as Non-Executive Director

Here's Why It's Unlikely That Clariane SE's (EPA:CLARI) CEO Will See A Pay Rise This Year

Clariane SE (EPA:CLARI) Shares Could Be 33% Below Their Intrinsic Value Estimate

Market Participants Recognise Clariane SE's (EPA:CLARI) Revenues Pushing Shares 187% Higher

Clariane (EPA:CLARI) Takes On Some Risk With Its Use Of Debt

Price target decreased by 12% to €3.83

Clariane Confirms Rumor of Disposal of HAD/SSIAD Business in France

Price target decreased by 11% to €4.01

Full year 2023 earnings released

Elevation Healthcare Properties managed by Elevation Advisors signed an agreement to acquire Berkley Care Group Ltd from Clariane SE (ENXTPA:CLARI) for £207 million.

Investor sentiment deteriorates as stock falls 22%

Investor sentiment deteriorates as stock falls 18%

Clariane SE to Report First Half, 2024 Results on Jul 30, 2024

Is It Too Late To Consider Buying Clariane SE (EPA:CLARI)?

Price target decreased by 22% to €6.73

Investor sentiment deteriorates as stock falls 17%

These 4 Measures Indicate That Clariane (EPA:CLARI) Is Using Debt Extensively

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 31%

Clariane SE to Report Fiscal Year 2023 Results on Feb 28, 2024

Now 20% undervalued after recent price drop

Calculating The Fair Value Of Clariane SE (EPA:CLARI)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 11% to €10.44

Consensus EPS estimates fall by 82%

What Is Clariane SE's (EPA:CLARI) Share Price Doing?

First half 2023 earnings released

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Upcoming dividend of €0.25 per share at 3.3% yield

Consensus EPS estimates increase by 18%

Now 21% undervalued after recent price drop

At €6.98, Is It Time To Put Korian (EPA:KORI) On Your Watch List?

These 4 Measures Indicate That Korian (EPA:KORI) Is Using Debt Extensively

Consensus EPS estimates increase by 20%

Price target decreased by 11% to €20.50

Investor sentiment deteriorates as stock falls 19%

Consensus EPS estimates fall by 50%, revenue upgraded

Price target decreased by 8.2% to €21.63

Full year 2022 earnings released

Price target decreased by 7.4% to €21.94

A Look At The Fair Value Of Korian (EPA:KORI)

Korian (ENXTPA:KORI) acquired Grupo 5 Acción y Gestión Social, S.A. from Corpfin Capital Asesores, S.A., SGEIC and others.

Should You Think About Buying Korian (EPA:KORI) Now?

Korian to Report First Half, 2023 Results on Jul 27, 2023

Does Korian (EPA:KORI) Have A Healthy Balance Sheet?

Consensus forecasts updated

Price target decreased to €24.69

Investor sentiment deteriorated over the past week

Is There Now An Opportunity In Korian (EPA:KORI)?

Is Korian (EPA:KORI) A Risky Investment?

First half 2022 earnings released

Korian Appoints Philippe Lévêque as Director and Chairman of the Ethics, Quality and CSR Committee

Upcoming dividend of €0.35 per share

Why Korian (EPA:KORI) Could Be Worth Watching

Investor sentiment deteriorated over the past week